Clinical Trial Update: Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring first-line combination therapy of toripalimab (PD-1 inhibitor) with anlotinib for hepatocellular carcinoma in patients who are …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shen Feng | Conditions: Hepatocellular Cancer | Phase 2 | Status: UNKNOWN